|
SuperGen today announced at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, that SGI-1252, its JAK2 kinase inhibitor, prevents tumor cell proliferation in vivo
DUBLIN, CA, USA | June 16, 2008 | SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, that SGI-1252, its JAK2 kinase inhibitor, prevents tumor cell proliferation in vivo (abstract #741).
In an oral presentation titled "SGI-1252: A Potent Small Molecule JAK2 Inhibitor," Dr. Steven Warner, Manager of Discovery Biology, highlighted how SuperGen scientists used the company's CLIMB(TM) technology to identify SGI-1252 as a possible JAK2 inhibitor. Dr. Warner presented data indicating that SGI-1252 selectively inhibits wildtype and mutant JAK2 activity in cancer cell lines, resulting in inhibition of STAT5 phosphorylation as well as a reduction in Bcl-XL expression. SGI-1252 was also shown to prevent tumor growth in mouse xenograft models. Pharmacokinetic studies indicate that SGI-1252 is orally bioavailable.
"SGI-1252 has shown potent and selective inhibition of JAK2 cellular signaling pathways that are involved in cancer cell proliferation. Moreover, as SGI-1252 does not target JAK3, we expect no negative clinical impact on patients' immune systems," said Dr. James Manuso, SuperGen's President and CEO. "We are optimistic that SGI-1252 may be effective in treating leukemia, lymphoma and myeloproliferative disorders and look forward to advancing this promising candidate into the clinic."
About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
SOURCE: SuperGen Inc. |
